BioSpace News Archive

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Agenus executives will conduct a conference call to discuss the global licensing agreement between Agenus and Bristol Myers Squibb at 8:30 a.m. ET today.

Abeona Therapeutics today announced financial results for the first quarter 2021 and recent business progress.

Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol ® Combination Therapy for Presbyopia Provides Broader Protection for Nyxol ® Across Indications on Methods of Use as Daily Administration

Cryoport, Inc., a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, announced the expansion of its global supply chain network with the acquisition of F-Airgate, a provider of innovative temperature-controlled supply chain solutions, headquartered in Brussels, Belgium.

DarioHealth Corp., a pioneer in the global digital therapeutics market, announced it has entered into an agreement to acquire PsyInnovations, Inc., a behavioral health digital platform that includes AI-enabled screening to triage and navigate members to specific interventions, digital Cognitive Behavioral Therapy, self-directed care, expert coaching and access to in-person and telehealth provider visits.

Phase 3 randomized withdrawal trial for cardiomyopathy in Barth planned ReCLAIM Phase 1 data presented at ARVO 2021 supports ReCLAIM-2 Phase 2 geographic atrophy trial design; data from fully enrolled ReCLAIM-2 trial expected second quarter of 2022

Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Companys CEO, John Temperato will present a corporate update at Oppenheimers Rare & Orphan Disease Summit and invites investors to participate via webcast and in one-on-one meetings.

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that that the Company will host a virtual key opinion leader (“KOL”) webinar on BX003 for the treatment of inflammatory bowel disease (“IBD”) on Wednesday, May 26, 2021 at 8:00 AM EDT.

Mustang Bio, Inc. (“Mustang”) today announced that the first patient has been dosed in a clinical trial to establish the safety and feasibility of administering MB-101 (autologous IL13Rα2-CAR T cells) to patients with leptomeningeal brain tumors (e.g., glioblastoma, ependymoma or medulloblastoma).